Genomic instability, a hallmark of cancer, occurs preferentially at specific genomic regions known as common fragile sites (CFSs). CFSs are evolutionarily conserved and late replicating regions with AT-rich sequences, and CFS instability is correlated with cancer. In the last decade, much progress has been made toward understanding the mechanisms of chromosomal instability at CFSs. However, despite tremendous efforts, identifying a cancer-associated CFS gene (CACG) remains a challenge and little is known about the function of CACGs at most CFS loci. Recent studies of FATS (for Fragile-site Associated Tumor Suppressor), a new CACG at FRA10F, reveal an active role of this CACG in regulating DNA damage checkpoints and suppressing tumorigenesis. The identification of FATS may inspire more discoveries of other uncharacterized CACGs. Further elucidation of the biological functions and clinical significance of CACGs may be exploited for cancer biomarkers and therapeutic benefits.
References
[1]
Schwartz, M.; Zlotorynski, E.; Kerem, B. The molecular basis of common and rare fragile sites. Cancer Lett 2006, 232, 13–26.
Glover, T.W.; Berger, C.; Coyle, J.; Echo, B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet 1984, 67, 136–142.
[4]
Kremer, E.J.; Pritchard, M.; Lynch, M.; Yu, S.; Holman, K.; Baker, E.; Warren, S.T.; Schlessinger, D.; Sutherland, G.R.; Richards, R.I. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 1991, 252, 1711–1714.
Denison, S.R.; Simper, R.K.; Greenbaum, I.F. How common are common fragile sites in humans: Interindividual variation in the distribution of aphidicolin-induced fragile sites. Cytogenet. Genome Res 2003, 101, 8–16.
Hashash, N.; Johnson, A.L.; Cha, R.S. Regulation of fragile sites expression in budding yeast by MEC1, RRM3 and hydroxyurea. J. Cell Sci 2011, 124, 181–185.
[9]
Glover, T.W.; Stein, C.K. Induction of sister chromatid exchanges at common fragile sites. Am. J. Hum. Genet 1987, 41, 882–890.
[10]
Glover, T.W.; Stein, C.K. Chromosome breakage and recombination at fragile sites. Am. J. Hum. Genet 1988, 43, 265–273.
[11]
Wang, N.D.; Testa, J.R.; Smith, D.I. Determination of the specificity of aphidicolin-induced breakage of the human 3p14.2 fragile site. Genomics 1993, 17, 341–347.
[12]
Chan, K.L.; Palmai-Pallag, T.; Ying, S.; Hickson, I.D. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat. Cell. Biol 2009, 11, 753–760.
[13]
Coquelle, A.; Pipiras, E.; Toledo, F.; Buttin, G.; Debatisse, M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 1997, 89, 215–225.
[14]
Hellman, A.; Zlotorynski, E.; Scherer, S.W.; Cheung, J.; Vincent, J.B.; Smith, D.I.; Trakhtenbrot, L.; Kerem, B. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 2002, 1, 89–97.
[15]
Bartova, E.; Galiova, G.; Legartova, S.; Stixova, L.; Jugova, A.; Kozubek, S. Genomic instability in the context of chromatin structure and fragile sites. Crit. Rev. Eukaryot. Gene Expr 2010, 20, 181–194.
[16]
Wilke, C.M.; Hall, B.K.; Hoge, A.; Paradee, W.; Smith, D.I.; Glover, T.W. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: Direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet 1996, 5, 187–195.
[17]
De Braekeleer, M.; Sreekantaiah, C.; Haas, O. Herpes simplex virus and human papillomavirus sites correlate with chromosomal breakpoints in human cervical carcinoma. Cancer Genet. Cytogenet 1992, 59, 135–137.
[18]
Popescu, N.C.; DiPaolo, J.A. Preferential sites for viral integration on mammalian genome. Cancer Genet. Cytogenet 1989, 42, 157–137.
[19]
Smith, P.P.; Friedman, C.; Bryant, E.M.; McDougall, J.K. Viral integration and fragile sites in human papillomavirus-immortalized human keratinocyte cell lines. Genes Chromosomes Cancer 1992, 5, 150–157.
[20]
Le Beau, M.M.; Rassool, F.V.; Neilly, M.E.; Espinosa, R.; Glover, T.W.; Smith, D.I.; McKeithan, T.W. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: Implications for the mechanism of fragile site induction. Hum. Mol. Genet 1998, 7, 755–761.
[21]
Wang, L.; Darling, J.; Zhang, J.S.; Huang, H.; Liu, W.; Smith, D.I. Allele-specific late replication and fragility of the most active common fragile site, FRA3B. Hum. Mol. Genet 1999, 8, 431–437.
[22]
Palakodeti, A.; Han, Y.; Jiang, Y.; Le Beau, M.M. The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer 2004, 39, 71–76.
[23]
Hellman, A.; Rahat, A.; Scherer, S.W.; Darvasi, A.; Tsui, L.C.; Kerem, B. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol. Cell. Biol 2000, 20, 4420–4427.
[24]
Pelliccia, F.; Bosco, N.; Curatolo, A.; Rocchi, A. Replication timing of two human common fragile sites: FRA1H and FRA2G. Cytogenet. Genome Res 2008, 121, 196–200.
[25]
Palumbo, E.; Matricardi, L.; Tosoni, E.; Bensimon, A.; Russo, A. Replication dynamics at common fragile site FAR6E. Chromosoma 2010, 119, 575–587.
[26]
Zlotorynski, E.; Rahat, A.; Skaug, J.; Ben-Porat, N.; Ozeri, E.; Hershberg, R.; Levi, A.; Scherer, S.W.; Margalit, H.; Kerem, B. Molecular basis for expression of common and rare fragile sites. Mol. Cell. Biol 2003, 23, 7143–7151.
[27]
Mishmar, D.; Rahat, A.; Scherer, S.W.; Nyakatura, G.; Hinzmann, B.; Kohwi, Y.; Mandel-Gutfroind, Y.; Lee, J.R.; Drescher, B.; Sas, D.E.; et al. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc. Natl. Acad. Sci. USA 1998, 95, 8141–8146.
[28]
Tsai, A.G.; Engelhart, A.E.; Hatmal, M.M.; Houston, S.I.; Hud, N.V.; Haworth, I.S.; Lieber, M.R. Conformational variants of duplex DNA correlated with cytosine-rich chromosomal fragile sites. J. Biol. Chem 2009, 284, 7157–7164.
[29]
Zhang, H.; Freudenreich, C.H. An AT-rich sequence in human common fragile site FRA16D causes fork stalling and chromosome breakage in S. cerevisiae. Mol. Cell 2007, 27, 367–379.
Bichara, M.; Wagner, J.; Lambert, I.B. Mechanisms of tandem repeat instability in bacteria. Mutation Res 2006, 598, 144–163.
[32]
Kang, S.; Jaworski, A.; Ohshima, K.; Wells, R.D. Expansion and deletion of CTG repeats from human disease genes are determined by the direction of replication in E. coli. Nat. Genet 1995, 10, 213–218.
[33]
Ragland, R.L.; Glynn, M.W.; Arlt, M.F.; Glover, T.W. Stably transfected common fragile site sequences exhibit instability at ectopic sites. Genes Chromosomes Cancer 2008, 47, 860–872.
[34]
Letessier, A.; Millot, G.A.; Koundrioukoff, S.; Lachagès, A.M.; Vogt, N.; Hansen, R.S.; Malfoy, B.; Brison, O.; Debatisse, M. Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature 2011, 470, 120–123.
[35]
Palakodeti, A.; Lucas, I.; Jiang, Y.; Young, D.J.; Fernald, A.A.; Karrison, T.; Le Beau, M.M. Impaired replication dynamics at the FRA3B common fragile site. Hum. Mol. Genet 2010, 19, 99–110.
[36]
Helmrich, A.; Ballarino, M.; Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 2011, 44, 966–977.
[37]
Ozeri-Galai, E.; Lebofsky, R.; Rahat, A.; Bester, A.C.; Bensimon, A.; Kerem, B. Failure of origin activation in response to fork stalling leads to chromosomal instability at fragile sites. Mol. Cell 2011, 43, 122–131.
[38]
Ozeri-Galai, E.; Bester, A.C.; Kerem, B. The complex basis underlying common fragile site instability in cancer. Trends Genet 2012, 28, 295–302.
[39]
Franchitto, A.; Pichierri, P. Understanding the molecular basis of common fragile sites instability: Role of the proteins involved in the recovery of stalled replication forks. Cell Cycle 2011, 10, 4039–4046.
[40]
Le Tallec, B.; Dutrillaux, B.; Lachages, A.M.; Millot, G.A.; Brison, O.; Debatisse, M. Molecular profiling of common fragile sites in human fibroblasts. Nat. Struct. Mol. Biol 2011, 18, 1421–1423.
[41]
Debatisse, M.; Le Tallec, B.; Letessier, A.; Dutrillaux, B.; Brison, O. Common fragile sites: Mechanisms of instability revisited. Trends Genet 2012, 28, 22–32.
[42]
Yunis, J.J; Soreng, A.L.; Bowe, A.E. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene 1987, 1, 59–69.
[43]
Druck, T.; Hadaczek, P.; Fu, T.B.; Ohta, M.; Siprashvili, Z.; Baffa, R.; Negrini, M.; Kastury, K.; Veronese, M.L.; Rosen, D.; et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997, 57, 504–512.
[44]
Michael, D.; Beer, D.G.; Wilke, C.W.; Miller, D.E.; Glover, T.W. Frequent deletions of FHIT and FRA3B in Barrett’s metaplasia and esophageal adenocarcinomas. Oncogene 1997, 15, 1653–1659.
[45]
Mimori, K.; Druck, T.; Inoue, H.; Alder, H.; Berk, L.; Mori, M.; Huebner, K.; Croce, C.M. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc. Natl. Acad. Sci. USA 1999, 96, 7456–7461.
[46]
Ohta, M.; Inoue, H.; Cotticelli, M.G.; Kastury, K.; Baffa, R.; Palazzo, J.; Siprashvili, Z.; Mori, M.; McCue, P.; Druck, T.; et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84, 587–597.
[47]
Roy, D.; Sin, S.H.; Damania, B.; Dittmer, D.P. Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood 2011, 118, e32–39.
[48]
Huiping, C.; Kristjansdottir, S.; Bergthorsson, J.T.; Jonasson, J.G.; Magnusson, J.; Egilsson, V.; Ingvarsson, S. High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur. J. Cancer 2002, 38, 728–735.
[49]
Barnes, L.D.; Garrison, P.N.; Siprashvili, Z.; Guranowski, A.; Robinson, A.K.; Ingram, S.W.; Croce, C.M.; Ohta, M.; Huebner, K. FHIT, a putative tumor suppressor in humans, is a dinucleoside 5′,5″′-P1,P3-triphosphate hydrolase. Biochemistry 1996, 35, 11529–11535.
[50]
Zanesi, N.; Fidanza, V.; Fong, L.Y.; Mancini, R.; Druck, T.; Valtieri, M.; Rüdiger, T.; McCue, P.A.; Croce, C.M.; Huebner, K. The tumor spectrum in FHIT-deficient mice. Proc. Natl. Acad. Sci. USA 2001, 98, 10250–10255.
[51]
Siprashvili, Z.; Sozzi, G.; Barnes, L.D.; McCue, P.; Robinson, A.K.; Eryomin, V.; Sard, L.; Tagliabue, E.; Greco, A.; Fusetti, L.; et al. Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA 1997, 94, 13771–13776.
[52]
Weiske, J.; Albring, K.F.; Huber, O. The tumor suppressor FHIT acts as a repressor of β-catenin transcriptional activity. Proc. Natl. Acad. Sci. USA 2007, 104, 20344–20349.
[53]
Jayachandran, G.; Sazaki, J.; Nishizaki, M.; Xu, K.; Girard, L.; Minna, J.D.; Roth, J.A.; Ji, L. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res 2007, 67, 10379–10388.
[54]
Bednarek, A.K.; Laflin, K.J.; Daniel, R.L.; Liao, Q.; Hawkins, K.A.; Aldaz, C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res 2000, 60, 2140–2145.
[55]
Ried, K.; Finnis, M.; Hobson, L.; Mangelsdorf, M.; Dayan, S.; Nancarrow, J.K.; Woollatt, E.; Kremmidiotis, G.; Gardner, A.; Venter, D.; et al. Common chromosomal fragile site FRA16D sequence: Identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet 2000, 9, 1651–1663.
[56]
Kuroki, T.; Trapasso, F.; Shiraishi, T.; Alder, H.; Mimori, K.; Mori, M.; Croce, C.M. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002, 62, 2258–2260.
[57]
Kuroki, T.; Yendamuri, S.; Trapasso, F.; Matsuyama, A.; Aqeilan, R.I.; Alder, H.; Rattan, S.; Cesari, R.; Nolli, M.L.; Williams, N.N.; et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin. Cancer Res 2004, 10, 2459–2465.
[58]
Aqeilan, R.I.; Kuroki, T.; Pekarsky, Y.; Albagha, O.; Trapasso, F.; Baffa, R.; Huebner, K.; Edmonds, P.; Croce, C.M. Loss of WWOX expression in gastric carcinoma. Clin. Cancer Res 2004, 10, 3053–3058.
[59]
Yendamuri, S.; Kuroki, T.; Trapasso, F.; Henry, A.C.; Dumon, K.R.; Huebner, K.; Williams, N.N.; Kaiser, L.R.; Croce, C.M. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 2003, 63, 878–881.
[60]
Watanabe, A.; Hippo, Y.; Taniguchi, H.; Iwanari, H.; Yashiro, M.; Hirakawa, K.; Kodama, T.; Aburatani, H. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003, 63, 8629–8633.
[61]
Aqeilan, R.I.; Hagan, J.P.; Aqeilan, H.A.; Pichiorri, F.; Fong, L.Y.; Croce, C.M. Inactivation of the WWOX gene accelerates forestomach tumor progression in vivo. Cancer Res 2007, 67, 5606–5610.
[62]
Aqeilan, R.I.; Trapasso, F.; Hussain, S.; Costinean, S.; Marshall, D.; Pekarsky, Y.; Hagan, J.P.; Zanesi, N.; Kaou, M.; Stein, G.S.; et al. Targeted deletion of WWOX reveals a tumor suppressor function. Proc. Natl. Acad. Sci. USA 2007, 104, 3949–3954.
[63]
Gourley, C.; Paige, A.J.; Taylor, K.J.; Scott, D.; Francis, N.J.; Rush, R.; Aldaz, C.M.; Smyth, J.F.; Gabra, H. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumor suppressor, although the role of variant 4 remains unclear. Int. J. Oncol 2005, 26, 1681–1689.
[64]
Bednarek, A.K.; Keck-Waggoner, C.L.; Daniel, R.L.; Laflin, K.J.; Bergsagel, P.L.; Kiguchi, K.; Brenner, A.J.; Aldaz, C.M. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001, 61, 8068–8073.
[65]
Ludes-Meyers, J.H.; Bednarek, A.K.; Popescu, N.C.; Bedford, M.; Aldaz, C.M. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet. Genome Res 2003, 100, 101–110.
Gaudio, E.; Palamarchuk, A.; Palumbo, T.; Trapasso, F.; Pekarsky, Y.; Croce, C.M.; Aqeilan, R.I. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res 2006, 66, 11585–11589.
[68]
Limongi, M.Z.; Pelliccia, F.; Rocchi, A. Characterization of the human common fragile site FRA2G. Genomics 2003, 81, 93–97.
[69]
Brueckner, L.M.; Sagulenko, E.; Hess, E.M.; Zheglo, D.; Blumrich, A.; Schwab, M.; Savelyeva, L. Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats. Hum. Genet 2012, 131, 1345–1359.
[70]
Rozier, L.; El-Achkar, E.; Apiou, F.; Debatisse, M. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: Possible association with an inherited disease and cancer. Oncogene 2004, 23, 6872–6880.
[71]
Denison, S.R.; Callahan, G.; Becker, N.A.; Phillips, L.A.; Smith, D.I. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 2003, 38, 40–52.
[72]
Morelli, C.; Karayianni, E.; Magnanini, C.; Mungall, A.J.; Thorland, E.; Negrini, M.; Smith, D.I.; Barbanti-Brodano, G. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 2002, 21, 7266–7276.
[73]
Bosco, N.; Pelliccia, F.; Rocchi, A. Characterization of FRA7B, a human common fragile site mapped at the 7p chromosome terminal region. Cancer Genet. Cytogenet 2010, 202, 47–52.
[74]
Huang, H.; Qian, C.; Jenkins, R.B.; Smith, D.I. Fish mapping of YAC clones at human chromosomal band 7q31.2: Identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosomes Cancer 1998, 21, 152–159.
[75]
Huang, H.; Reed, C.P.; Mordi, A.; Lomberk, G.; Wang, L.; Shridhar, V.; Hartmann, L.; Jenkins, R.; Smith, D.I. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 1999, 24, 48–55.
[76]
Miller, C.T.; Lin, L.; Casper, A.M.; Lim, J.; Thomas, D.G.; Orringer, M.B.; Chang, A.C.; Chambers, A.F.; Giordano, T.J.; Glover, T.W.; et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006, 25, 409–418.
[77]
Ciullo, M.; Debily, M.A.; Rozier, L.; Autiero, M.; Billault, A.; Mayau, V.; El Marhomy, S.; Guardiola, J.; Bernheim, A.; Coullin, P.; et al. Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: The model of PIP gene duplication from a break at FRA7I. Hum. Mol. Genet 2002, 11, 2887–2894.
[78]
Helmrich, A.; Stout-Weider, K.; Matthaei, A.; Hermann, K.; Heiden, T.; Schrock, E. Identification of the human/mouse syntenic common fragile site FRA7K/Fra12C1: Relation of FRA7K and other human common fragile sites on chromosome 7 to evolutionary breakpoints. Int. J. Cancer 2007, 120, 48–54.
[79]
Ferber, M.J.; Eilers, P.; Schuuring, E.; Fenton, J.A.; Fleuren, G.J.; Kenter, G.; Szuhai, K.; Smith, D.I.; Raap, A.K.; Brink, A.A. Positioning of cervical carcinoma and Burkitt lymphoma translocation breakpoints with respect to the human papillomavirus integration cluster in FRA8C at 8q24.13. Cancer Genet. Cytogenet 2004, 154, 1–9.
[80]
Ferber, M.J.; Thorland, E.C.; Brink, A.A.; Rapp, A.K.; Phillips, L.A.; McGovern, R.; Gostout, B.S.; Cheung, T.H.; Chung, T.K.; Fu, W.Y.; et al. Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene 2003, 22, 7233–7242.
[81]
Callahan, G.; Denison, S.R.; Phillips, L.A.; Shridhar, V.; Smith, D.I. Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 2003, 22, 590–601.
[82]
Li, Z.; Zhang, Q.; Mao, J.H.; Weise, A.; Mrasek, K.; Fan, X.; Zhang, X.; Liehr, T.; Lu, K.H.; Balmain, A.; et al. An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. Oncogene 2010, 29, 2659–2671.
[83]
Gandhi, M.; Dillon, L.W.; Pramanik, S.; Nikiforov, Y.E.; Wang, Y.H. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 2010, 29, 2272–2280.
[84]
Gandhi, M.; Medvedovic, M.; Stringer, J.R.; Nikiforov, Y.E. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 2006, 25, 2360–2366.
[85]
Arlt, M.F.; Miller, D.E.; Beer, D.G.; Glover, T.W. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 2002, 33, 82–92.
[86]
McAvoy, S.; Ganapathiraju, S.; Perez, D.S.; James, C.D.; Smith, D.I. DMD and IL1RAPL1: Two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors. Cytogenet. Genome Res 2007, 119, 196–203.
[87]
Mitsui, J.; Takahashi, Y.; Goto, J.; Tomiyama, H.; Ishikawa, S.; Yoshino, H.; Minami, N.; Smith, D.I.; Lesage, S.; Aburatani, H.; et al. Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am. J. Hum. Genet 2010, 87, 75–89.
Joo, K.M.; Jin, J.; Kim, E.; Ho Kim, K.; Kim, Y.; Gu Kang, B.; Kang, Y.J.; Lathia, J.D.; Ho Cheong, K.; Song, P.H.; et al. MET signaling regulates glioblastoma stem cells. Cancer Res 2012, 72, 3828–3838.
[90]
Tatarelli, C.; Linnenbach, A.; Mimori, K.; Croce, C.M. Characterization of the human TESTIN gene localized in the FRA7G region at 7q31.2. Genomics 2000, 68, 1–12.
[91]
Sarti, M.; Sevignani, C.; Calin, G.A.; Aqeilan, R.; Shimizu, M.; Pentimalli, F.; Picchio, M.C.; Godwin, A.; Rosenberg, A.; Drusco, A.; et al. Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clin. Cancer Res 2005, 11, 806–813.
[92]
Han, S.Y.; Druck, T.; Huebner, K. Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics 2003, 81, 105–107.
[93]
Meyer, N.; Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 2008, 8, 976–990.
[94]
Nyegaard, M.; Overgaard, M.T.; Su, Y.Q.; Hamilton, A.E.; Kwintkiewicz, J.; Hsieh, M.; Nayak, N.R.; Conti, M.; Conover, C.A.; Giudice, L.C. Lack of functional pregnancy-associated plasma protein-A (PAPPA) compromises mouse ovarian steroidogenesis and female fertility. Biol. Reprod 2010, 82, 1129–1138.
[95]
Santoro, M.; Melillo, R.M.; Fusco, A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology prize lecture. Eur. J. Endoc 2006, 155, 645–653.
[96]
Dillon, L.W.; Lehman, C.E.; Wang, Y.H. The role of fragile sites in sporadic papillary thyroid carcinoma. J. Thyroid Res 2012, 2012, 927683.
[97]
Dillon, L.W.; Burrow, A.A.; Wang, Y.H. DNA instability at chromosomal fragile sites in cancer. Curr. Genomics 2010, 11, 326–337.
[98]
Luo, Y.; Tsuchiya, K.D., Il; Park, D.; Fausel, R.; Kanngurn, S.; Welcsh, P.; Dzieciatkowski, S.; Wang, J.; Grady, W.M. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 2012, doi:10.1038/onc.2012.225.
[99]
Wagner, S.M.; Zhu, S.; Nicolescu, A.C.; Mulligan, L.M. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics (Sao Paulo) 2012, 67, 77–84.
[100]
Poulogiannis, G.; McIntyre, R.E.; Dimitriadi, M.; Apps, J.R.; Wilson, C.H.; Ichimura, K.; Luo, F.; Cantley, L.C.; Wyllie, A.H.; Adams, D.J.; et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc. Natl. Acad. Sci. USA 2010, 107, 15145–15150.
[101]
Veeriah, S.; Taylor, B.S.; Meng, S.; Fang, F.; Yilmaz, E.; Vivanco, I.; Janakiraman, M.; Schultz, N.; Hanrahan, A.J.; Pao, W.; et al. Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet 2010, 42, 77–82.
Kemp, C.J.; Wheldon, T.; Balmain, A. p53-Deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet 1994, 8, 66–69.
[104]
Cai, W.W.; Mao, J.H.; Chow, C.W.; Damani, S.; Balmain, A.; Bradley, A. Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat. Biotechnol 2002, 20, 393–396.
[105]
Maier, D.; Comparone, D.; Taylor, E.; Zhang, Z.; Gratzl, O.; van Meir, E.G.; Scott, R.J.; Merlo, A. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25–26. Oncogene 1997, 15, 997–1000.
[106]
Nagase, S.; Yamakawa, H.; Sato, S.; Yajima, A.; Horii, A. Identification of a 790-kilobase region of common allelic loss in chromosome 10q25-q26 in human endometrial cancer. Cancer Res 1997, 57, 1630–1633.
[107]
Zhang, X.; Zhang, Q.; Zhang, J.; Qiu, L.; Yan, S.S.; Feng, J.; Sun, Y.; Huang, X.; Lu, K.H.; Li, Z. FATS is a transcriptional target of p53 and associated with antitumor activity. Mol. Cancer 2010, 9, 244.
[108]
Zhang, J.; Gu, L.; Zhao, L.J.; Zhang, X.F.; Qiu, L.; Li, Z. Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer. Chin. Med. J 2011, 124, 2894–2898.
[109]
Tian, Y.; Zhang, J.; Yan, S.; Qiu, L.; Li, Z. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer. Lung Cancer 2012, 76, 416–422.
[110]
Mrasek, K.; Schoder, C.; Teichmann, A.C.; Behr, K.; Franze, B.; Wilhelm, K.; Blaurock, N.; Claussen, U.; Liehr, T.; Weise, A. Global screening and extended nomenclature for 230 aphidicolin-inducible fragile sites, including 61 yet unreported ones. Int. J. Oncol 2010, 36, 929–940.
[111]
Bignell, G.R.; Greenman, C.D.; Davies, H.; Butler, A.P.; Edkins, S.; Andrews, J.M.; Buck, G.; Chen, L.; Beare, D.; Latimer, C.; et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463, 893–898.
[112]
Tsantoulis, P.K.; Kotsinas, A.; Sfikakis, P.P.; Evangelou, K.; Sideridou, M.; Levy, B.; Mo, L.; Kittas, C.; Wu, X.R.; Papavassiliou, A.G.; et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions: A genome-wide study. Oncogene 2008, 27, 3256–3264.
[113]
Harrison, J.C.; Haber, J.E. Surviving the breakup: The DNA damage checkpoint. Annu. Rev. Genet 2006, 40, 209–235.
[114]
Glover, T.W.; Coyle-Morris, J.; Morgan, R. Fragile sites: Overview, occurrence in acute nonlymphocytic leukemia and effects of caffeine on expression. Cancer Genet. Cytogenet 1986, 19, 141–150.
[115]
Lemoine, F.J.; Degtyareva, N.P.; Kokoska, R.J.; Petes, T.D. Reduced levels of DNA polymerase delta induce chromosome fragile site instability in yeast. Mol. Cell. Biol 2008, 28, 5359–5368.
[116]
Rey, L.; Sidorova, J.M.; Puget, N.; Boudsocq, F.; Biard, D.S.; Monnat, R.J., Jr; Cazaux, C.; Hoffmann, J.S. Human DNA polymerase eta is required for common fragile site stability during unperturbed DNA replication. Mol. Cell. Biol. 2009, 29, 3344–3354.
Ozeri-Galai, E.; Schwartz, M.; Rahat, A.; Kerem, B. Interplay between ATM and ATR in the regulation of common fragile site stability. Oncogene 2008, 27, 2109–2117.
[119]
Wan, C.; Kulkarni, A.; Wang, Y.H. ATR preferentially interacts with common fragile site FRA3B and the binding requires its kinase activity in response to aphidicolin treatment. Mutat. Res 2010, 686, 39–46.
[120]
Durkin, S.G.; Arlt, M.F.; Howlett, N.G.; Glover, T.W. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006, 25, 4381–4388.
[121]
Zhu, M.; Weiss, R.S. Increased common fragile site expression, cell proliferation defects, and apoptosis following conditional inactivation of mouse Hus1 in primary cultured cells. Mol. Biol. Cell 2007, 18, 1044–1055.
[122]
Musio, A.; Montagna, C.; Mariani, T.; Tilenni, M.; Focarelli, M.L.; Brait, L.; Indino, E.; Benedetti, P.A.; Chessa, L.; Albertini, A.; et al. SMC1 involvement in fragile site expression. Hum. Mol. Genet 2005, 14, 525–533.
[123]
Arlt, M.F.; Xu, B.; Durkin, S.G.; Casper, A.M.; Kastan, M.B.; Glover, T.W. BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol. Cell. Biol 2004, 24, 6701–6709.
[124]
Focarelli, M.L.; Soza, S.; Mannini, L.; Paulis, M.; Montecucco, A.; Musio, A. Claspin inhibition leads to fragile site expression. Genes Chromosomes Cancer 2009, 48, 1083–1090.
[125]
Howlett, N.G.; Taniguchi, T.; Durkin, S.G.; D’Andrea, A.D.; Glover, T.W. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum. Mol. Genet 2005, 14, 693–701.
[126]
Schoder, C.; Liehr, T.; Velleuer, E.; Wilhelm, K.; Blaurock, N.; Weise, A.; Mrasek, K. New aspects on chromosomal instability: Chromosomal break-points in Fanconi anemia patients co-localize on the molecular level with fragile sites. Int. J. Oncol 2010, 36, 307–312.
[127]
Cangi, M.G.; Piccinin, S.; Pecciarini, L.; Talarico, A.; Dal Cin, E.; Grassi, S.; Grizzo, A.; Maestro, R.; Doglioni, C. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. Int. J. Cancer 2008, 123, 1466–1471.
[128]
Vernole, P.; Muzi, A.; Volpi, A.; Terrinoni, A.; Dorio, A.S.; Tentori, L.; Shah, G.M.; Graziani, G. Common fragile sites in colon cancer cell lines: Role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1. Mutat. Res 2011, 712, 40–48.
[129]
Cheng, E.; Vaisica, J.A.; Ou, J.; Baryshnikova, A.; Lu, Y.; Roth, F.P.; Brown, G.W. Genome rearrangements caused by depletion of essential DNA replication proteins in Saccharomyces cerevisiae. Genetics 2012, 192, 147–160.
[130]
Pirzio, L.M.; Pichierri, P.; Bignami, M.; Franchitto, A. Werner syndrome helicase activity is essential in maintaining fragile site stability. J. Cell Biol 2008, 180, 305–314.
[131]
Tuduri, S.; Crabbé, L.; Conti, C.; Tourrière, H.; Holtgreve-Grez, H.; Jauch, A.; Pantesco, V.; De Vos, J.; Thomas, A.; Theillet, C.; et al. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat. Cell Biol 2009, 11, 1315–1324.
[132]
Arlt, M.F.; Glover, T.W. Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites. DNA Repair 2010, 9, 678–689.
[133]
Murfuni, I.; De Santis, A.; Federico, M.; Bignami, M.; Pichierri, P.; Franchitto, A. Perturbed replication induced genome-wide or at common fragile sites is differently managed in the absence of WRN. Carcinogenesis 2012, 33, 1655–1663.
[134]
Shah, S.N.; Opresko, P.L.; Meng, X.; Lee, M.Y.; Eckert, K.A. DNA structure and the Werner protein modulate human DNA polymerase delta-dependent replication dynamics within the common fragile site FRA16D. Nucleic. Acids Res 2010, 38, 1149–1162.
[135]
Johnstone, R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov 2002, 1, 287–299.
[136]
Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res 2007, 5, 981–989.
Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K.W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282, 1497–1501.
[139]
Deng, C.; Zhang, P.; Harper, J.W.; Elledge, S.J.; Leder, P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82, 675–684.
[140]
Yan, S.; Ma, K.; Qiu, L.; Zhang, J.; Zhang, X.; Hao, X.; Li, Z. FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes p53-dependent checkpoint responseTo be submitted for publication. .
[141]
Thavathiru, E.; Ludes-Meyers, J.H.; MacLeod, M.C.; Aldaz, C.M. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol. Carcinog 2005, 44, 174–182.
[142]
Durkin, S.G.; Ragland, R.L.; Arlt, M.F.; Mulle, J.G.; Warren, S.T.; Glover, T.W. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc. Natl. Acad. Sci. USA 2008, 105, 246–251.
[143]
Geradts, J.; Fong, K.M.; Zimmerman, P.V.; Minna, J.D. Loss of FHIT expression in non-small-cell lung cancer: Correlation with molecular genetic abnormalities and clinicopathological features. Br. J. Cancer 2000, 82, 1191–1197.
[144]
Lee, Y.C.; Wu, C.T.; Shih, J.Y.; Jou, Y.S.; Chang, Y.L. Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers. Br. J. Cancer 2004, 90, 2378–2383.
[145]
Nunez, M.I.; Rosen, D.G.; Ludes-Meyers, J.H.; Abba, M.C.; Kil, H.; Page, R.; Klein-Szanto, A.J.; Godwin, A.K.; Liu, J.; Mills, G.B.; et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005, 5, 64.
[146]
Kaposi-Novak, P.; Lee, J.S.; Gòmez-Quiroz, L.; Coulouarn, C.; Factor, V.M.; Thorgeirsson, S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest 2006, 116, 1582–1595.
[147]
Boice, J.D., Jr; Morin, M.M.; Glass, A.G.; Friedman, G.D.; Stovall, M.; Hoover, R.N.; Fraumeni, J.F., Jr. Diagnostic X-ray procedures and risk of leukemia, lymphoma, and multiple myeloma. JAMA 1991, 265, 1290–1294.
[148]
Ron, E. Ionizing radiation and cancer risk: Evidence from epidemiology. Pediatr. Radiol 2002, 32, 232–237.
[149]
Pearce, M.S.; Salotti, J.A.; Little, M.P.; McHugh, K.; Lee, C.; Kim, K.P.; Howe, N.L.; Ronckers, C.M.; Rajaraman, P.; Craft, A.W.; et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: A retrospective cohort study. Lancet 2012, 380, 499–505.
